Cediranib
ASCO: Olaparib and cediranib combo promising for recurrent ovarian cancer
June 05, 2014For women with recurrent platinum-sensitive ovarian cancer, the combination of the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib is more effective than olaparib alone.
Cediranib improves survival in recurrent ovarian cancer
October 21, 2013Women with ovarian cancer that has recurred after chemotherapy survived longer after treatment with cediranib, a biological therapy, according to research.
Sign Up for Free e-newsletters
ONA Articles
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- American Association for Cancer Research Releases Its 2018 Annual Report
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- Use of Anti-inflammatory Analgesics Has a Positive Effect on Survival Outcomes in Ovarian Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |